Intractable

ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform…

Phase 2 trial of resiniferatoxin (RTX) to proceed following clearance from FDA.The decision is supported by the Phase 1 data confirming RTX safety for epidural administration without dose…